Skye Bioscience, Inc. (OTCQB: SKYE) CEO Punit Dhillon tells Proactive the San Diego, California-based biopharmaceutical company has changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc. Dhillon says the name change reflects how 'the sky is limitless' for the group's robust pipeline on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need.
Skye Bioscience name change from Emerald Bioscience reflects 'limitless' strategy to treat glaucoma
Quick facts: Skye Bioscience inc
Price: 0.1095 USD
Market Cap: $27.38 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE